Navigation Links
IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
Date:1/30/2008

SILVER SPRING, Md., Jan. 30 /PRNewswire-USNewswire/ -- Expanding the pipeline of HIV prevention tools in development, the International Partnership for Microbicides (IPM) today announced that Pfizer Inc. (Pfizer) has agreed to give IPM a royalty-free license to maraviroc, its newly-approved HIV treatment, as a microbicide for the prevention of HIV infection. Maraviroc, sold under the trade name Selzentry(TM)/Celsentri(R), is one of a new class of antiretroviral drugs known as CCR5 blockers, which works to prevent HIV infection by preventing the virus from gaining entry into target cells.

This agreement marks only the second time a pharmaceutical company has licensed an already approved HIV therapy to be developed as a microbicide. Researchers hope that maraviroc's safety and efficacy data as a therapeutic will speed its development as a microbicide.

"This agreement adds a promising new compound to IPM's pipeline, allowing us to explore new ways to prevent HIV infection," said Dr. Zeda Rosenberg, CEO of the International Partnership for Microbicides. "Pfizer and IPM's other industry partners deserve recognition for their significant leadership in the global effort to protect women from HIV."

Microbicides are products, such as gels and films, that could be applied vaginally to prevent transmission of HIV during vaginal intercourse. IPM is also developing other delivery methods such as long-lasting vaginal rings that release drug gradually over time.

"Pfizer is proud to contribute to the effort to develop a safe and effective microbicide with the potential to give women around the world new ways to protect themselves from HIV," said Pfizer Vice President Dr. Jack Watters. "Given maraviroc's mechanism of action blocking entry of HIV into the CD4 cells, the possibility for use in a microbicide is exciting. In addition to developing new drugs to treat AIDS, we are committed to searching for ways our drugs can be used to slow down
'/>"/>

SOURCE International Partnership for Microbicides
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Spiritual Healer/Psychic-Medium Reaches International Status!
2. EMBL reaches north
3. AK Steel Reaches VEBA Health Care Settlement With Middletown Works Retirees
4. Sun Safety Awareness Reaches New Heights at Plano Hot Air Balloon Festival
5. 40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode
6. Blue Cross of California Reaches Out to Members Impacted by Southern California Fires
7. Free Site Offering Patient-Physician Dialog Reaches Milestone
8. Sharp HealthCare Foundation Reaches $50 Million Goal
9. Nyer Medical Group Reaches Agreement to Acquire Minority Interest in Pharmacy Chain Subsidiary
10. MB Software Corporation Reaches Agreement with Keystone Equity Partners
11. New York City death rate reaches historic low
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... discovery by Northwestern Medicine scientists could lead to potential ... in people with scleroderma. , Fibrosis, or scarring, ... of the skin and lungs can lead to serious ... concept for new therapeutic options centers on findings made ... who identified the role that a specific protein plays ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... (PORTLAND, Ore.) October 27, 2008 Elderly people who have ... abstention from tobacco, moderate to higher income and no ... their old age, according to a study in ... Medical Sciences . , The first study of its ...
... took them were less likely to get venous thromboembolism ... of drugs widely used to lower cholesterol may have ... breast, lung, colon and other solid-organ cancers. , Research ... Philadelphia found that cancer patients taking statins had a ...
... Reduce the Risk of a Subsequent Stroke, AUSTIN, ... launch of The TIA (Transient Ischemic Attack) Center for,Stroke ... of its kind in,Central Texas -- in an effort ... TIA., A TIA is a "warning stroke" or ...
... Incomparable Nutrient Value for Less Than 25 Cents A ... ... just released by,consulting firm Booz & Company confirmed that U.S. consumers have ... one,third of consumers have made measurable cutbacks in frequent purchases,such as dining ...
... Data presented at the joint annual meeting of ICAAC and ... effective as Prevnar for,the seven shared serotypes, and provide expanded ... complete U.S. filing for pediatric use in the first,quarter of ... or possibly earlier, WASHINGTON, Oct. 27 Data from ...
... ... Finds, RICHMOND, Va., Oct. 27 Eighty-four ... funding will be an important factor in determining how they cast,their vote in ... to 64 sponsored by Genworth Financial, Inc.,(NYSE: GNW )., According to ...
Cached Medicine News:Health News:Study reveals factors of exceptional health in old age 2Health News:Statins Lower Risk of Clots in Cancer Patients 2Health News:St. David's HealthCare Launches The TIA Center for Stroke Prevention at St. David's Medical Center 2Health News:St. David's HealthCare Launches The TIA Center for Stroke Prevention at St. David's Medical Center 3Health News:No Need to Forego Nutrition in Tight Economic Times 2Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 2Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 3Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 4Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 5Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 6Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 7Health News:Survey Reveals Long Term Care Key Issue for Voters in Presidential Election 2Health News:Survey Reveals Long Term Care Key Issue for Voters in Presidential Election 3
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 2, 2011 Doctors should consider using catheterization as ... in diagnosing children with heart defects, according to a ... (Logo: http://photos.prnewswire.com/prnh/20100222/AHSALOGO ) A catheter is ... and used in procedures such as angiography, in which ...
... Lpath, Inc. (OTCBB: LPTN), the category leader ... President and CEO, will present at RetailInvestorConferences.com.DATE: ... EDTLINK: , www.retailinvestorconferences.com >Click the red "register/ ... interactive online event where investors are invited to ...
Cached Medicine Technology:Catheterization Recommended for Treating Pediatric Heart Conditions 2Catheterization Recommended for Treating Pediatric Heart Conditions 3Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th 2Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th 3
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
Round knurled handle. Overall length 130 mm....
Medicine Products: